Statements (50)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:pharmaceuticals
|
| gptkbp:approves |
gptkb:2003
gptkb:FDA |
| gptkbp:available_on |
gptkb:tablet
oral suspension film-coated tablet |
| gptkbp:brand |
gptkb:Cialis
Adcirca |
| gptkbp:casnumber |
171596-29-5
|
| gptkbp:chemical_formula |
C22 H19 N3 O4 S
|
| gptkbp:clinical_trial |
erectile dysfunction studies
pulmonary arterial hypertension studies |
| gptkbp:contraindication |
nitrates
severe cardiovascular disorders |
| gptkbp:dosage_form |
10 mg
5 mg 20 mg 2.5 mg |
| gptkbp:duration |
up to 36 hours
as needed daily use |
| gptkbp:excretion |
urine
|
| https://www.w3.org/2000/01/rdf-schema#label |
Tadalafil
|
| gptkbp:interacts_with |
antihypertensives
alpha-blockers other PDE5 inhibitors |
| gptkbp:invention |
gptkb:2020
|
| gptkbp:lifespan |
17.5 hours
|
| gptkbp:marketed_as |
gptkb:Eli_Lilly_and_Company
|
| gptkbp:mechanism_of_action |
PDE5 inhibitor
|
| gptkbp:metabolism |
liver
|
| gptkbp:research_areas |
pharmacology
cardiovascular health sexual health urology pulmonology |
| gptkbp:route_of_administration |
oral
|
| gptkbp:side_effect |
headache
back pain muscle aches flushing dyspepsia |
| gptkbp:structure |
gptkb:Bastiladon
phenyl group methyl group pyrimidine |
| gptkbp:used_for |
treatment of erectile dysfunction
treatment of pulmonary arterial hypertension |
| gptkbp:bfsParent |
gptkb:Lilly_ICOS
|
| gptkbp:bfsLayer |
6
|